Ligelizumab 120 mg + Ligelizumab 240 mg
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Food Allergy
Conditions
Food Allergy
Trial Timeline
Apr 27, 2023 → Mar 6, 2025
NCT ID
NCT05678959About Ligelizumab 120 mg + Ligelizumab 240 mg
Ligelizumab 120 mg + Ligelizumab 240 mg is a phase 3 stage product being developed by Novartis for Food Allergy. The current trial status is terminated. This product is registered under clinical trial identifier NCT05678959. Target conditions include Food Allergy.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05678959 | Phase 3 | Terminated |
Competing Products
17 competing products in Food Allergy